These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 28684643

  • 1. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
    Nanishi E, Nishio H, Takada H, Yamamura K, Fukazawa M, Furuno K, Mizuno Y, Saigo K, Kadoya R, Ohbuchi N, Onoe Y, Yamashita H, Nakayama H, Hara T, Ohno T, Takahashi Y, Hatae K, Harada T, Shimose T, Kishimoto J, Ohga S, Hara T.
    J Am Heart Assoc; 2017 Jul 06; 6(7):. PubMed ID: 28684643
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
    Lancet Child Adolesc Health; 2018 Dec 06; 2(12):855-862. PubMed ID: 30337183
    [Abstract] [Full Text] [Related]

  • 3. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S, KIDCARE Multicenter Study Group.
    Lancet Child Adolesc Health; 2021 Dec 06; 5(12):852-861. PubMed ID: 34715057
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
    Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A, KAICA trial Investigators.
    Lancet; 2019 Mar 16; 393(10176):1128-1137. PubMed ID: 30853151
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcomes of initial dexamethasone treatment combined with a single high dose of intravenous immunoglobulin for primary treatment of Kawasaki disease.
    Lim YJ, Jung JW.
    Yonsei Med J; 2014 Sep 16; 55(5):1260-6. PubMed ID: 25048483
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial.
    Fukui S, Seki M, Minami T, Kotani K, Oka K, Yokomizo A, Matsubara D, Sato T, Nozaki Y, Saito M, Kikuchi Y, Miyamoto K, Monden Y, Yamagata T.
    Pediatr Rheumatol Online J; 2021 Jul 03; 19(1):107. PubMed ID: 34217297
    [Abstract] [Full Text] [Related]

  • 7. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
    Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
    [Abstract] [Full Text] [Related]

  • 8. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
    Roberts SC, Jain S, Tremoulet AH, Kim KK, Burns JC, KIDCARE Multicenter Study Group, Anand V, Anderson M, Ang J, Ansusinha E, Arditi M, Ashouri N, Bartlett A, Chatterjee A, DeBiasi R, Dekker C, DeZure C, Didion L, Dominguez S, El Feghaly R, Erdem G, Halasa N, Harahsheh A, Jackson MA, Jaggi P, Jain S, Jone PN, Kaushik N, Kurio G, Lillian A, Lloyd D, Manaloor J, McNelis A, Michalik DE, Newburger J, Newcomer C, Perkins T, Portman M, Romero J, Ronis T, Rowley A, Schneider K, Schuster J, Tejtel SKS, Sharma K, Simonsen K, Szmuszkovicz J, Truong D, Wood J, Yeh S.
    Contemp Clin Trials; 2019 Apr 17; 79():98-103. PubMed ID: 30840903
    [Abstract] [Full Text] [Related]

  • 9. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.
    Sundel RP, Baker AL, Fulton DR, Newburger JW.
    J Pediatr; 2003 Jun 17; 142(6):611-6. PubMed ID: 12838187
    [Abstract] [Full Text] [Related]

  • 10. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
    Li X, Tang Y, Ding Y, Chen Y, Hou M, Sun L, Qian G, Qin L, Lv H.
    Eur J Pharmacol; 2021 May 15; 899():173985. PubMed ID: 33652059
    [Abstract] [Full Text] [Related]

  • 11. High-dose aspirin for Kawasaki disease: outdated myth or effective aid?
    Amarilyo G, Koren Y, Brik Simon D, Bar-Meir M, Bahat H, Helou MH, Mendelson A, Hezkelo N, Chodick G, Berkun Y, Eisenstein E, Butbul Aviel Y, Barkai G, Bolkier Y, Padeh S, Brik R, Hashkes PJ, Harel L, Uziel Y.
    Clin Exp Rheumatol; 2017 May 15; 35 Suppl 103(1):209-212. PubMed ID: 28079513
    [Abstract] [Full Text] [Related]

  • 12. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH.
    PLoS One; 2015 May 15; 10(12):e0144603. PubMed ID: 26658843
    [Abstract] [Full Text] [Related]

  • 13. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
    Manlhiot C, Yeung RS, Chahal N, McCrindle BW.
    Pediatr Allergy Immunol; 2010 May 15; 21(3):515-21. PubMed ID: 20546528
    [Abstract] [Full Text] [Related]

  • 14. Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8+ T cell activation in Kawasaki disease.
    Ye Q, Gong FQ, Shang SQ, Hu J.
    Clin Immunol; 2016 Oct 15; 171():25-31. PubMed ID: 27519954
    [Abstract] [Full Text] [Related]

  • 15. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.
    Inoue Y, Okada Y, Shinohara M, Kobayashi T, Kobayashi T, Tomomasa T, Takeuchi K, Morikawa A.
    J Pediatr; 2006 Sep 15; 149(3):336-341. PubMed ID: 16939743
    [Abstract] [Full Text] [Related]

  • 16. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
    Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX.
    Zhonghua Er Ke Za Zhi; 2006 Dec 15; 44(12):891-5. PubMed ID: 17254453
    [Abstract] [Full Text] [Related]

  • 17. Resistance to intravenous immunoglobulin (IVIG) in Kawasaki disease: no influence of different IVIG lot utilisation.
    Pagnini I, Marino A, Simonini G, Cimaz R.
    Clin Exp Rheumatol; 2012 Dec 15; 30(1 Suppl 70):S170. PubMed ID: 22410254
    [No Abstract] [Full Text] [Related]

  • 18. Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.
    Iio K, Morikawa Y, Miyata K, Kaneko T, Misawa M, Yamagishi H, Miura M.
    J Pediatr; 2022 Jan 15; 240():158-163.e4. PubMed ID: 34461064
    [Abstract] [Full Text] [Related]

  • 19. Risk Factors of Coronary Artery Abnormalities and Resistance to Intravenous Immunoglobulin Plus Corticosteroid Therapy in Severe Kawasaki Disease: An Analysis of Post RAISE.
    Miyata K, Miura M, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H.
    Circ Cardiovasc Qual Outcomes; 2021 Feb 15; 14(2):e007191. PubMed ID: 33541111
    [Abstract] [Full Text] [Related]

  • 20. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial.
    Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M.
    Pediatrics; 2012 Jan 15; 129(1):e17-23. PubMed ID: 22144699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.